# Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

> **NCT02559973** · PHASE1 · COMPLETED · sponsor: **Indivior Inc.** · enrollment: 47 (actual)

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** RBP-6000
- **DRUG:** SUBOXONE Sublingual Film

## Key facts

- **NCT ID:** NCT02559973
- **Lead sponsor:** Indivior Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-02
- **Final completion:** 2016-03
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2017-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02559973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02559973, "Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder". Retrieved via AI Analytics 2026-08-25 from https://api.ai-analytics.org/clinical/NCT02559973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*